Thomas Feldthus joins WntResearch as CFO

Press release from Companies

Published: 2012-07-11 09:05:26

WntResearch AB: Thomas Feldthus joins WntResearch as CFO

WntResearch AB (WNT.ST) announces that Thomas Feldthus accepts the position as CFO of WntResearch. Thomas has more than two decades of experience within the Life Science Industry. He has been the co-founder of 3 biotech companies including Danish Symphogen A/S where he served as CFO for 12 years raising more than 200M Euros in venture capital and negotiating numerous collaboration agreements including a 300M USD agreement with Genentech. Thomas holds a M.Sc. from the Technical University of Denmark and a MBA from London Business School. The employment of Thomas Feldthus will add strong business skills and an international network to investors and potential partners. Thomas will work 2 days a week for the Company.

CEO Nils Brünner comments: I'm very happy that we have been able to attract a capacity as Thomas Feldthus as a CFO of the Company. Thomas is a highly respected entrepreneur in Danish biotech he has a proven and successful track record of raising capital and has a strong international network. I believe that Thomas has exactly the skills and background that together with the WntR team will bring the Companies anti cancer programs forward and thereby create value for our investors. For further information please contact: Nils Brünner, CEO E-mail: nbr@wntresearch.com Telephone: +45 2614 4708 or Peter Buhl Jensen, Chairman of the Board E-mail: pbj@buhloncology.com Telephone: +45 2160 8922 About WntResearch AB WntResearch (WNT.ST) is a public company listed at the AktieTorget and is a research based Biotech Company spun out of Lund University, Sweden, founded in 2007. The focus and aim of WntResearch is to develop novel anti-metastatic therapies, in areas of unmet need, for the treatment of cancer patients. The company has two major drug development projects, Foxy-5 and Box-5. The lead project Foxy-5 is currently being tested in in-vivo models and is planned to enter phase 1 clinical trials in metastatic cancer in 2012.